Bictegravir and Lenacapavir
Brand names: Bixlenvo Sunlenca Starter Pack · Active ingredient: Bictegravir Sodium, Lenacapavir Sodium
In short: BIXLENVO SUNLENCA STARTER PACK is a co-packaged product containing BIXLENVO and SUNLENCA tablets and is indicated for the initiation of BIXLENVO, a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in t
What is Bictegravir and Lenacapavir used for?
BIXLENVO SUNLENCA STARTER PACK is a co-packaged product containing BIXLENVO and SUNLENCA tablets and is indicated for the initiation of BIXLENVO, a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO .
Bictegravir and Lenacapavir dosage
The BIXLENVO dosing schedule in adults requires a two-day initiation regimen of BIXLENVO tablets plus SUNLENCA tablets taken orally, followed by a maintenance regimen of one tablet of BIXLENVO taken orally once daily (Table 1). BIXLENVO must be taken with SUNLENCA during the two-day initiation period. BIXLENVO and SUNLENCA tablets may be taken with or without food .
Treatment Time
Dosage: Initiation
Day 1 | BIXLENVO 75 mg/50 mg (1 tablet) orally and SUNLENCA 600 mg orally (2 × 300 mg tablets)
Day 2 | BIXLENVO 75 mg/50 mg (1 tablet) orally and SUNLENCA 600 mg orally (2 × 300 mg tablets)
Dosage: Maintenance
Day 3 and thereafter | BIXLENVO 75 mg/50 mg (1 tablet) orally once daily
After completion of the initial 30-day treatment with the STARTER PACK, BIXLENVO should be used for continued maintenance dosing.
Missed Initiation Dose
During the initiation period, if the Day 1 or Day 2 doses of BIXLENVO or SUNLENCA are missed, patients should take them as soon as possible . Patients should not take Day 1 and Day 2 doses of SUNLENCA on the same day.
Missed Maintenance Dose
If a maintenance dose of BIXLENVO is missed, patients should take it as soon as possible. If more than 7 days have elapsed since the last maintenance dose, restart the initiation dosage regimen from Day 1, if clinically appropriate to continue BIXLENVO treatment .
Lower exposures of BIC were observed during pregnancy; therefore, viral load should be monitored closely in pregnant individuals [see Drug Interactions (7.4), Use in Specific Populations (8.1), and Clinical Pharmacology (12.3)].
How to take Bictegravir and Lenacapavir — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Drug Interactions
BIXLENVO SUNLENCA STARTER PACK may interact with certain drugs; therefore, advise patients to report to their healthcare provider the use of any other prescription or non-prescription medication or herbal products, including St. John’s wort, during treatment with BIXLENVO SUNLENCA STARTER PACK .
Dosing: Initiation Regimen and Missed Dose
Counsel patients that it is important to take both BIXLENVO and SUNLENCA tablets during initiation. Advise patients that the BIXLENVO SUNLENCA STARTER PACK should only be used for the initiation or restart of treatment and the patient will be on maintenance dosing with BIXLENVO after the first month .
Counsel patients to take BIXLENVO on a regular dosing schedule with or without food and to avoid missing doses as it can result in development of resistance. Patients should contact their healthcare provider if more than 7 days have elapsed since their last dose of BIXLENVO .
Pregnancy Registry
Inform patients that there is an antiretroviral pregnancy registry to monitor fetal outcomes of pregnant individuals exposed to BIXLENVO or SUNLENCA . …
Warnings & precautions
Do not take this medicine if: Concomitant administration of BIXLENVO is contraindicated with:
dofetilide due to the potential for increased dofetilide plasma concentrations and associated serious and/or life-threatening events.
strong CYP3A inducers due to decreased plasma concentrations of BIC and LEN, which may result in the loss of therapeutic effect and development of resistance to BIXLENVO.
The concomitant use of BIXLENVO with certain other drugs may result in known or potentially significant drug interactions, some of which may lead to :
Loss of therapeutic effect of BIXLENVO and possible development of resistance.
Possible clinically significant adverse reactions from greater exposures of concomitant drugs.
See Table 4 for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations. Consider the potential for drug interactions prior to and during BIXLENVO therapy; review concomitant medications during BIXLENVO therapy; and monitor for the adverse reactions associated with the concomitant drugs.
Bictegravir and Lenacapavir side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The primary safety assessment of BIXLENVO in virologically suppressed adults with HIV-1 was based on 48-week data from participants in two Phase 3 randomized active-controlled clinical trials, ARTISTRY-1 (N=557) and ARTISTRY-2 (N=574) . ARTISTRY-1 was an open-label trial that enrolled participants who had been on a stable baseline regimen for at least 6 months and were randomized to receive BIXLENVO or to continue their stable baseline regimen. ARTISTRY-2 was a blinded trial that enrolled participants who had been on BIKTARVY for at least 6 months at baseline and were randomized to receive BIXLENVO or to continue BIKTARVY.
The most common adverse reactions (all grades) reported in greater than or equal to 2% of participants in any treatment group from ARTISTRY-1 and ARTISTRY-2 through Week 48 are presented in Table 2. The side-by-side tabulation is to simplify presentation; direct comparison across trials should not be made due to differing trial designs.
ARTISTRY-1ARTISTRY-1 was open-label with a stable baseline regimen as the comparator. | ARTISTRY-2 ARTISTRY-2 was blinded with BIKTARVY as the comparator. …
Drug interactions
Because BIXLENVO SUNLENCA STARTER PACK is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended .
Bictegravir (BIC), a component of BIXLENVO, inhibits organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE1) in vitro. Coadministration of BIC with drugs that are substrates of OCT2 and MATE1 (e.g., dofetilide) may increase their plasma concentrations .
Lenacapavir (LEN), a component of BIXLENVO and of SUNLENCA, is a moderate inhibitor of CYP3A and a P-gp inhibitor. Coadministration of LEN with sensitive substrates of CYP3A or P-gp may increase the concentrations of these substrates and result in the increased risk of their adverse events. See the prescribing information of these sensitive substrates for dosing recommendations or appropriate monitoring of safety.
BIC is a substrate of CYP3A and UGT1A1. LEN is a substrate of P-gp, UGT1A1, and CYP3A.
Strong or Moderate CYP3A Inducers
A drug that is a strong inducer of CYP3A and also an inducer of UGT1A1 can substantially decrease the plasma concentrations of BIC. Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of LEN . …
About this medicine
BIXLENVO SUNLENCA STARTER PACK contains BIXLENVO and SUNLENCA. BIXLENVO tablets contain bictegravir (BIC) sodium and lenacapavir (LEN) sodium for oral administration. SUNLENCA tablets contain LEN for oral administration .
BIC is an integrase strand-transfer inhibitor (INSTI).
LEN is a capsid inhibitor.
Bictegravir sodium:
The chemical name of bictegravir sodium is 2,5-Methanopyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, 2,3,4,5,7,9,13,13a-octahydro-8-hydroxy-7,9-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-, sodium salt (1:1), (2R,5S,13aR)-.
Bictegravir sodium has a molecular formula of C21H17F3N3NaO5 and a molecular weight of 471.4 and has the following structural formula:
Bictegravir sodium is an off-white to yellow solid with a solubility of 0.1 mg per mL in water at 20°C. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b2a3ef0e-3ded-45d7-9ba6-f33c4d372dc1. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin